KalVista Pharmaceuticals' Chief Commercial Officer, Nicole Sweeny, completed the sale of 1,862 shares of the company's common stock on April 17, 2026. The shares transacted at $20.2163 apiece, producing total gross proceeds of $37,642.
This disposition came immediately after a vesting and settlement event on April 16, 2026, in which Ms. Sweeny acquired 6,250 shares through the settlement of restricted stock units (RSUs). Each RSU carried the contingent right to receive one share of the issuer's common stock upon settlement for no consideration.
Company filings indicate that the April 17 sale was carried out to satisfy tax withholding liabilities generated by the RSU vesting and settlement. The records specify that the sale was not a discretionary transaction by Ms. Sweeny but rather a transfer executed to cover the associated tax obligations.
After the RSU settlement and the subsequent sale to meet withholding requirements, Ms. Sweeny is recorded as directly holding 51,391 shares of KalVista common stock.
KalVista's stock has traded close to its 52-week high of $21.30, reflecting roughly a 74% return over the prior 12 months as of the time of these transactions. Independent analysis cited in company commentary suggests the shares appear undervalued on a Fair Value basis, and a forecast included in that analysis projects revenue growth of 164% for fiscal year 2026.
Several commercial and clinical updates accompany the insider activity. KalVista reported strong fourth-quarter fiscal 2025 results for its Ekterly product, with sales of $35 million that exceeded consensus expectations of about $21 million. The company also disclosed global Ekterly sales of $49 million through the end of 2025.
Analyst coverage referenced alongside these results includes a Market Outperform rating from Citizens with a $28.00 price target, a Buy rating from H.C. Wainwright with a $37.00 price target, and a price target increase to $42 from Stifel, each highlighting market demand for Ekterly as the first oral, on-demand treatment for hereditary angioedema. Separately, Citizens is noted as having adjusted its price target slightly to $28.00 while maintaining a positive view on the Ekterly launch.
On the clinical front, KalVista also presented interim data from the KONFIDENT-KID trial, assessing Ekterly for pediatric hereditary angioedema, with the results cited as showing promising symptom relief.
The sequence of an RSU settlement followed by a tax-driven sale is a common mechanism for executives to satisfy withholding requirements without indicating a discretionary decision to reduce ownership. In this instance, the company-level updates on Ekterly commercialization and analyst price target activity provide context around the stock's recent trading level and investor interest.